Long-term Study of Guselkumab in Children with Arthritis
Phase 3
196
about 7.1 years
3+
4 sites in GA, IN, OH +1
What this study is about
Researchers are testing the safety of a medication called guselkumab in children who have arthritis, including juvenile arthritis, psoriatic arthritis, ulcerative colitis, or Crohn's disease. The trial will last for 2600 days and involve approximately 196 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Guselkumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
guselkumab
injection, intravenous
Primary: Number of Participants with Treatment-Emergent Adverse Events as Assessment of Safety
Dermatology, Gastroenterology, Immune, Musculoskeletal